There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm
As the International NASH day draws more attention to NASH, it’s important to remember that hepatocarcinoma (HCC) is the 2nd most common cause of cancer related death. Dr M. Peiseler and Dr F. Tacke, Charité hospital, Berlin, Germany present the latest scientific information about NASH as a systemic disease, represented by a common inflammatory ‘NAFLD phenotype’ of myeloid cells in liver and bone marrow. They highlight the role of inflammation and its multiple markers.
Prof Tacke, Germany reviews the epidemiological challenge of NAFLD and NASH worldwide, especially with the obesity pandemic. He describes the clinical impact of inflammation and fibrosis in NAFLD and the role of macrophages. Finally, he discusses the possible therapeutic implications. Credit : 4th global NASH congress 2021
It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.
n this great pedagogical video, Prof Chris Byrne, UK illustrates that NAFLD is a risk factor for other extra hepatic diseases beyond the liver. He explains the natural history of NAFLD and shows that it is a multisystem disease with effects beyond the liver: risk of extra-hepatic complications (CVD, T2DM, CKD, and certain cancers)
As the 28th European congress on Obesity draws near, Prof Cusi, USA explains a paradigm shift and why drugs that have had an impact for CV disease also have a significant potential in the management of NASH. Amongst them, PPARs may have a role to play in addition to management of obesity and lifestyle interventions.
In this very comprehensive video, Prof. Kenneth Cusi, USA, reviews the guidelines on NAFLD that are currently being updated. He also shares highlights on the rationale of PPARs in NASH and discusses the clinical trials with Pioglitazone. He addresses the positive results as well as the misconceptions and barriers for using PPAR-γ in NASH.
Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.